Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
eNrdWFtv2jAUfudXoLw7CZdymQLVxtoNqdUYLdq0F2TiAzELceoL0P36OQld6RTEarA09SVKbOc7J8ff+c5xgsvtKq6ugQvKkp5Tc32nCknICE0WPWdyf406zmW/EizxGu8t0+vcet2phjEWoudks+4McCLc77c3H0G/D9zpV6oBmy0hlC/WKUlj9zMW0S1OszXVYM0oqa5ARoz0nFTJfLQaCMm1F/0N4z9FikMIvN3I/uxy2twfD7wM7B9QlQB+g5NFKeicG2GGinNI5ABLWDD+WA4dTmv1C9/vdI1MUDEGwRQPYYRlNOJsTQmQcks4FmBkZL4hd8DXMcjMSCm4twxXwggcL/F2DA/Dcqff69mB3Erko1q7duHXmy0dq1bLyBTfC1U5efRHeOm04bdb7W7bm3OPQEgzjqOk7te6yK81Wh4JPQErRBRqoqWisY4Lymf1SMj04wIQARRjFGElAekL41TmgwIn+iZlXOobhAlLZYZOkEoAzWkY5atmekgJnOEotAJCQ7zSRDJkyCizFlviBhWDlyy3ZIfDw1EOEirSGD+6S5GahgpzHWkJXGuRvQ/JvuCea3WMdcz+wk9UHHuv9Hqy0y5LHmfSOGAqkQck7HpsGogB09mwPbyjZqortzsuUhDng/3FkvKKM1KzmIamwqqlT4GQk/HwsK6+PUn6gAVMuD1N+kYTwjbi/Fq3zy1L3uc7EZeCZjy46HQb5i3OD83iA6X2SnGWgqclkIpTlG2YzNmpmqYToxzqKS3eWEbk3ScLcQwH+s+pocjqVHhql60lm71ELiZKQT9d3ZuS9KsC/niXP5ZCU9L7Qy+zCmSjrOmUOOZ4oRy901SiADl2Zql32s1Oo2NGdl6ubpGUqXjneZvNxo2wKNLQ1fn9n9fAy7PEXReXZ9rYO8hZabmKFrSoLZZcnxUdw+uIY6oQx5qyUw8au/d3B5pSG5IrOGEvimJiTfKHV+evIs+nDGtuj15omz0z+YkAZxJiq0dUs4MNonnd0vuaXHMtEF/mWvPgdbwMvOLfXr8SeNl/vX7lN2zOsKQ=
rcc0PLkrky1ZWz0N